They address the various external forces that effect the adoption and discontinuation
of performance funding programs.
Factors linked to reduced likelihood of warfarin discontinuation
included comorbid atrial fibrillation, which was associated with a 25% reduction in risk of discontinuation
; thrombophilia, with a 34% relative risk reduction; and pulmonary embolism, with a 24% reduction in discontinuation
compared to patients with DVT only.
Thus, the effects of access to and composition of available methods on relevant discontinuations
are transmitted through the use of these methods.
Side effects were the most often reported reason for discontinuation
21%), accounting for over one-third of discontinuations
among women using oral contraceptive pills, injectables, and the IUD.
Hemorrhagic complications were the main reasons for discontinuation
in 110 patients--41 (29%) of those aged 80 years and older and 69 (21%) of those aged younger than 80 years.
The incidence of discontinuations
due to edema-related adverse events was significantly higher only for ARCOXIA 90 mg compared to diclofenac, and not with the 60 mg dose.
We hypothesize that many discontinuations
are associated with low motivation to avoid pregnancy; this would be reflected in a significant proportion of pregnancies following discontinuation
being reported as intended.
Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, which may require discontinuation
Severe infusion reactions require immediate and permanent discontinuation
of ERBITUX therapy.
Patients on atazanavir and lopinavir/ritonavir plus Truvada should be monitored for Truvada-associated adverse events that may require discontinuation
Revenue declines were due to a combination of capacity constraints in focus products, as well as pricing pressures, past discontinuations
and other efforts to reduce exposure within commodity products.
due to adverse events were statistically greater in the 10 mg/kg/day group (36 of 111) versus the 3 mg/kg/day group (23 of 115; p=0.
of study drug due to adverse events were more common in the abacavir (n=3, hypersensitivity reactions) vs.
WASHINGTON -- Gilead Sciences (Nasdaq:GILD) today announced the presentation of 24-week data from an ongoing clinical trial (Study 934) that suggest treatment-naive patients with HIV who received a once-a-day regimen of Viread(R) (tenofovir disoproxil fumarate 300 mg), Emtriva(R) (emtricitabine 200 mg) and efavirenz (600 mg) had fewer adverse event-related study discontinuations
compared to those who received a regimen of twice-daily Combivir(R) (lamivudine 150 mg/zidovudine 300 mg) and once-daily efavirenz (600 mg).
During the initial 24 weeks, the severity and incidence of adverse events and laboratory abnormalities, as well as the incidence of discontinuations
from study for adverse events, were similar (less than or equal to 3 percent) between the Viread and placebo groups.